Concordance of CSF Measures of Alzheimer's Pathology with Amyloid PET Status in a Preclinical Cohort: A Comparison of Lumipulse and Established Immunoassays

Overview

Journal Alzheimers Dement (Amst)

Date 2021 Feb 18

PMID 33598527

Citations 19

Authors

Ashvini Keshavan

Henrietta Wellington

Zhongbo Chen

Ayesha Khatun

Miles Chapman

Melanie Hart

David M Cash

William Coath

Thomas D Parker

Sarah M Buchanan

Sarah E Keuss

Matthew J Harris

Heidi Murray-Smith

Amanda Heslegrave

Nick C Fox

Henrik Zetterberg

Jonathan M Schott

Affiliations

Soon will be listed here.

Abstract

Introduction: We assessed the concordance of cerebrospinal fluid (CSF) amyloid beta (Aβ) and tau measured on the fully automated Lumipulse platform with pre-symptomatic Alzheimer's disease (AD) pathology on amyloid positron emission tomography (PET).

Methods: In 72 individuals from the Insight 46 study, CSF Aβ40, Aβ42, total tau (t-tau), and phosphorylated tau at site 181 (p-tau181) were measured using Lumipulse, INNOTEST, and Meso Scale Discovery (MSD) assays and inter-platform Pearson correlations derived. Lumipulse Aβ42 measures were adjusted to incorporate standardization to certified reference materials. Logistic regressions and receiver operating characteristics analysis generated CSF cut-points optimizing concordance with F-florbetapir amyloid PET status (n = 63).

Results: Measurements of CSF Aβ, p-tau181, and their ratios correlated well across platforms (r 0.84 to 0.94, < .0001); those of t-tau and t-tau/Aβ42 correlated moderately (r 0.57 to 0.79, < .0001). The best concordance with amyloid PET (100% sensitivity and 94% specificity) was afforded by cut-points of 0.075 for Lumipulse Aβ42/Aβ40, 0.087 for MSD Aβ42/Aβ40 and 17.3 for Lumipulse Aβ42/p-tau181.

Discussion: The Lumipulse platform provides comparable sensitivity and specificity to established CSF immunoassays in identifying pre-symptomatic AD pathology.

Citing Articles

Distinctive associations between plasma p-tau181 levels and hippocampal subfield volume across the Alzheimer's disease continuum.

Rich A, Oh H bioRxiv. 2025; .

PMID: 39975208 PMC: 11838288. DOI: 10.1101/2025.01.27.635113.

Plasma biomarkers of amyloid, tau, astrogliosis, and axonal injury in a mixed memory clinic cohort.

Gleerup H, Simonsen A, Grotschel L, Gramkow M, Hogh P, Blennow K Alzheimers Dement (Amst). 2025; 17(1):e70073.

PMID: 39822295 PMC: 11736635. DOI: 10.1002/dad2.70073.

Longitudinal trajectory of plasma p-tau217 in cognitively unimpaired subjects.

Martinez-Dubarbie F, Guerra-Ruiz A, Lopez-Garcia S, Lage C, Fernandez-Matarrubia M, Pozueta-Cantudo A Alzheimers Res Ther. 2024; 16(1):268.

PMID: 39702464 PMC: 11661039. DOI: 10.1186/s13195-024-01642-1.

Longitudinal plasma phosphorylated-tau217 and other related biomarkers in a non-demented Alzheimer's risk-enhanced sample.

Du L, Langhough R, Wilson R, Rea Reyes R, Hermann B, Jonaitis E Alzheimers Dement. 2024; 20(9):6183-6204.

PMID: 38970274 PMC: 11497664. DOI: 10.1002/alz.14100.

Relationship Between Cerebrospinal Fluid Alzheimer's Disease Biomarker Values Measured via Lumipulse Assays and Conventional ELISA: Single-Center Experience and Systematic Review.

Kurihara M, Kondo S, Ohse K, Nojima H, Kikkawa-Saito E, Iwata A J Alzheimers Dis. 2024; 99(3):1077-1092.

PMID: 38759016 PMC: 11191528. DOI: 10.3233/JAD-240185.

References

Agnello L, Piccoli T, Vidali M, Cuffaro L, Lo Sasso B, Iacolino G . Diagnostic accuracy of cerebrospinal fluid biomarkers measured by chemiluminescent enzyme immunoassay for Alzheimer disease diagnosis. Scand J Clin Lab Invest. 2020; 80(4):313-317. DOI: 10.1080/00365513.2020.1740939. View

Delaby C, Munoz L, Torres S, Nadal A, Le Bastard N, Lehmann S . Impact of CSF storage volume on the analysis of Alzheimer's disease biomarkers on an automated platform. Clin Chim Acta. 2018; 490:98-101. DOI: 10.1016/j.cca.2018.12.021. View

James S, Lane C, Parker T, Lu K, Collins J, Murray-Smith H . Using a birth cohort to study brain health and preclinical dementia: recruitment and participation rates in Insight 46. BMC Res Notes. 2018; 11(1):885. PMC: 6293512. DOI: 10.1186/s13104-018-3995-0. View

Lane C, Parker T, Cash D, Macpherson K, Donnachie E, Murray-Smith H . Study protocol: Insight 46 - a neuroscience sub-study of the MRC National Survey of Health and Development. BMC Neurol. 2017; 17(1):75. PMC: 5395844. DOI: 10.1186/s12883-017-0846-x. View

Toombs J, Foiani M, Wellington H, Paterson R, Arber C, Heslegrave A . Amyloid β peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios. Alzheimers Dement (Amst). 2018; 10:311-321. PMC: 5956932. DOI: 10.1016/j.dadm.2018.02.005. View

Janelidze S, Zetterberg H, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O . CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol. 2016; 3(3):154-65. PMC: 4774260. DOI: 10.1002/acn3.274. View

Kaplow J, Vandijck M, Gray J, Kanekiyo M, Huyck E, Traynham C . Concordance of Lumipulse cerebrospinal fluid t-tau/Aβ42 ratio with amyloid PET status. Alzheimers Dement. 2020; 16(1):144-152. PMC: 7061432. DOI: 10.1002/alz.12000. View

Kollhoff A, Howell J, Hu W . Automation vs. Experience: Measuring Alzheimer's Beta-Amyloid 1-42 Peptide in the CSF. Front Aging Neurosci. 2018; 10:253. PMC: 6113375. DOI: 10.3389/fnagi.2018.00253. View

Lane C, Barnes J, Nicholas J, Sudre C, Cash D, Parker T . Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study. Lancet Neurol. 2019; 18(10):942-952. PMC: 6744368. DOI: 10.1016/S1474-4422(19)30228-5. View

10.

Dubois B, Feldman H, Jacova C, Hampel H, Molinuevo J, Blennow K . Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014; 13(6):614-29. DOI: 10.1016/S1474-4422(14)70090-0. View

11.

Keshavan A, Wellington H, Chen Z, Khatun A, Chapman M, Hart M . Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays. Alzheimers Dement (Amst). 2021; 13(1):e12131. PMC: 7867115. DOI: 10.1002/dad2.12131. View

12.

Boulo S, Kuhlmann J, Andreasson U, Brix B, Venkataraman I, Herbst V . First amyloid β1-42 certified reference material for re-calibrating commercial immunoassays. Alzheimers Dement. 2020; 16(11):1493-1503. PMC: 7984389. DOI: 10.1002/alz.12145. View

13.

Palmqvist S, Mattsson N, Hansson O . Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography. Brain. 2016; 139(Pt 4):1226-36. PMC: 4806222. DOI: 10.1093/brain/aww015. View

14.

Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P . Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease. Alzheimers Res Ther. 2019; 11(1):34. PMC: 6477717. DOI: 10.1186/s13195-019-0485-0. View

15.

Janelidze S, Pannee J, Mikulskis A, Chiao P, Zetterberg H, Blennow K . Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment. JAMA Neurol. 2017; 74(12):1492-1501. PMC: 5822196. DOI: 10.1001/jamaneurol.2017.2814. View

16.

Clark C, Pontecorvo M, Beach T, Bedell B, Coleman R, Doraiswamy P . Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol. 2012; 11(8):669-78. DOI: 10.1016/S1474-4422(12)70142-4. View

17.

Mattsson N, Andreasson U, Persson S, Arai H, Batish S, Bernardini S . The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement. 2011; 7(4):386-395.e6. PMC: 3710290. DOI: 10.1016/j.jalz.2011.05.2243. View

18.

Lewczuk P, Lelental N, Spitzer P, Maler J, Kornhuber J . Amyloid-β 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays. J Alzheimers Dis. 2014; 43(1):183-91. DOI: 10.3233/JAD-140771. View

19.

Cullen V, Fredenburg R, Evans C, Conliffe P, Solomon M . Development and advanced validation of an optimized method for the quantitation of Aβ42 in human cerebrospinal fluid. AAPS J. 2012; 14(3):510-8. PMC: 3385823. DOI: 10.1208/s12248-012-9360-7. View

20.

Leitao M, Silva-Spinola A, Santana I, Olmedo V, Nadal A, Le Bastard N . Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease. Alzheimers Res Ther. 2019; 11(1):91. PMC: 6875031. DOI: 10.1186/s13195-019-0550-8. View